Sharmila Patel
Overview
Explore the profile of Sharmila Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voorhees P, Sborov D, Laubach J, Kaufman J, Reeves B, Rodriguez C, et al.
Future Oncol
. 2024 Oct;
21(1):25-49.
PMID: 39452950
No abstract available.
2.
Badros A, Badros A, Foster L, Anderson Jr L, Chaulagain C, Pettijohn E, et al.
Blood
. 2024 Sep;
145(3):300-310.
PMID: 39331724
No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study...
3.
Chari A, Kaufman J, Laubach J, Sborov D, Reeves B, Rodriguez C, et al.
Blood Cancer J
. 2024 Jul;
14(1):107.
PMID: 38977707
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of...
4.
Callander N, Silbermann R, Kaufman J, Godby K, Laubach J, Schmidt T, et al.
Blood Cancer J
. 2024 Apr;
14(1):69.
PMID: 38649340
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present...
5.
Silbermann R, Laubach J, Kaufman J, Sborov D, Reeves B, Rodriguez C, et al.
Am J Hematol
. 2024 Apr;
99(7):1257-1268.
PMID: 38622840
In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and progression-free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone...
6.
Nooka A, Kaufman J, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, et al.
Br J Haematol
. 2024 Mar;
204(6):2227-2232.
PMID: 38504552
Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that...
7.
Voorhees P, Sborov D, Laubach J, Kaufman J, Reeves B, Rodriguez C, et al.
Lancet Haematol
. 2023 Sep;
10(10):e825-e837.
PMID: 37708911
Background: Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly...
8.
Nooka A, Kaufman J, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, et al.
Future Oncol
. 2023 Feb;
18(40):4443-4456.
PMID: 36799429
What Is This Summary About?: This is a summary of a publication about Black participants of the GRIFFIN clinical study that was published in in April 2022. The GRIFFIN clinical...
9.
Chhabra S, Callander N, Watts N, Costa L, Thapa B, Kaufman J, et al.
Transplant Cell Ther
. 2022 Dec;
29(3):174.e1-174.e10.
PMID: 36494017
For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is...
10.
Ran T, Medhekar R, Fu A, Patel S, Kaila S
Future Oncol
. 2022 Nov;
18(36):3983-3991.
PMID: 36377712
To evaluate among multiple myeloma (MM) patients, the proportions with first-line bortezomib/lenalidomide/dexamethasone (VRd) dose modifications and the associated baseline patient characteristics. Adult MM patients treated with first-line VRd were selected...